This study is currently recruiting participants.
Number
06-CH-0011
Sponsoring Institute
National Institute of Child Health and Human Development (NICHD)
Recruitment Detail
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 1 days Max Age: 99 Years
Referral Letter Required
No
Population Exclusion(s)
None
Keywords
Congenital Adrenal Hyperplasia (CAH); Familial Male Precocious Puberty (FMPP); 21-Hydroxylase Deficiency; Adrenal Insufficiency; Natural History
Recruitment Keyword(s)
Congenital Adrenal Hyperplasia; CAH; Familial Male Precocious Puberty; FMPP
Condition(s)
Congenital Adrenal Hyperplasia (CAH); Familial Male-Limited Precocious Puberty (FMPP)
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Supporting Site
National Institute of Child Health and Human Development
Patients with known or suspected CAH due to 21-hydroxylase deficiency, 11- hydroxylase deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency and males with known or suspected FMPP may be eligible for this study. Patients with both classic and non-classic CAH are eligible, and patients with androgen excess of unknown cause may be eligible.
Participants undergo the following procedures:
-Medical history and physical examination.
-Fasting blood tests for analysis of hormones, blood chemistries including blood sugar and cardiovascular risk factors such as lipids.
-Oral glucose tolerance test for patients with elevated insulin levels. For this test, a catheter (plastic tube) is placed in a vein in the patient's arm. The patient drinks a sugar-containing fluid and blood samples are collected through the catheter at intervals starting with drinking the solution, and then 30, 60 and 120 minutes after drinking the solution.
-24-hour urine collection to measure hormone levels in the urine.
-DNA testing for patients with 21-hydroxylase deficiency to help identify the type of genetic mutation responsible for the disease.
-X-ray of the left hand to measure bone age in growing children. The x-ray is used to determine how far into puberty the child is and how much growth potential is left in the bones.
-A pelvic ultrasound in females and testicular ultrasound in males to evaluate the size and development of the gonads (ovaries in females and testes in males).
-Cognitive and psychological tests, including an IQ test and evaluation of memory, achievement and behavior.
-Other tests and evaluations based on medical need.
The schedule for these procedures varies. In a part of the study involving only patients with CAH, growing children are evaluated twice (once in childhood and once after reaching adult height), and adults are evaluated once. In another part of the study involving patients with CAH and FMPP, growing children are seen twice a year, and adults and children who have reached adult height may be seen annually. Additional visits may be scheduled if medically indicated. In this part of the study, females are asked to keep a record of their periods after their first menstrual cycle.
--Back to Top--
INCLUSION CRITERIA: 1) Males, ages 0 - 99 with known or suspected FMPP or 2) Patients (males and females, ages 0 - 99) with known or suspected (based on hormonal, clinical and/or genetic testing) CAH of any type. 3) Patients with excess androgen of unknown etiology or 4) Relatives of patients in this protocol. EXCLUSION CRITERIA: 1) Females with isolated polycystic ovary syndrome. If, following a diagnostic work-up, a patient is determined to have PCOS as the only cause of her hyperandrogenism; she will no longer be followed on this protocol. 2) Patients with significant non-endocrine medical conditions. 3) Females who are pregnant at the time of initial enrollment.
1) Males, ages 0 - 99 with known or suspected FMPP or
2) Patients (males and females, ages 0 - 99) with known or suspected (based on hormonal, clinical and/or genetic testing) CAH of any type.
3) Patients with excess androgen of unknown etiology or
4) Relatives of patients in this protocol.
EXCLUSION CRITERIA:
1) Females with isolated polycystic ovary syndrome. If, following a diagnostic work-up, a patient is determined to have PCOS as the only cause of her hyperandrogenism; she will no longer be followed on this protocol.
2) Patients with significant non-endocrine medical conditions.
3) Females who are pregnant at the time of initial enrollment.
Principal Investigator
Referral Contact
For more information: